Kenvue shares falls back by 10% in the RFK Jr. Tylenol Autism Report
Kenvue Inc. Tylenol Brand Pain Reliever for sale in a pharmacy in New York, USA, on Wednesday, March 27, 2024.
Bloomberg | Bloomberg | Getty pictures
Shares of Kenvue On Friday, more than 10%fell after a report that the secretary for health and human services, Robert F. Kennedy Jr., is probably linked to the use of the company’s pain reliever medication in pregnant women.
HHS will publish the report that could draw this month this month, reported the Wall Street Journal on Friday.
This report also suggests that a medication that has been obtained from folkat and water-soluble vitamin sound journal for the treatment of symptoms of developmental disorder can be used in some people.
In an explanation, an HHS spokesman said: “We use the gold standard science to get to the bottom of the unprecedented increase in the autism rates of America.”
“Until we publish the final report, all claims about its content are nothing more than speculation,” they added.
Tylenol could be the youngest widespread and accepted treatment, which Kennedy undermined at the head of HHS, which monitors the federal health authorities, regulate drugs and other therapies. Kennedy has also taken steps to change the vaccine guideline in the USA and intensify incorrect claims about secure and effective recordings that MRNA technology use.
Kennedy has made the disorder an important focus of HHS and in April promises that the agency “will know what the autism epidemic caused in September” and eliminates the exposure. He also said this month that the agency initiated a “massive test and research effort” in which hundreds of scientists worldwide are involved in the cause.
In a statement, Kenvue said that science “continuously evaluated and continuously evaluated [continues] To believe that there is no causal connection between the use of paracetamol, the generic name for Tylenol during pregnancy and autism.
The company added that the Food and Drug Administration and the leading medical organizations agree on the security of the drug, its use during pregnancy and the information on the Tylenol label.
According to the FDA website, the agency has not found any “clear evidence” that adequately use of paracetamol during pregnancy “disadvantageous pregnancy, birth, neurobiorus or development results” causes. However, the FDA said pregnant women speak to their health service providers before using over -the -counter medication.
The American College of Obstricians and Gynecologists claims that paracetamol is safe during pregnancy if they are instructed and taken after advising a health service provider.
Some earlier studies have proposed that the medicine represents risks to the development of the fetus, and some parents have filed complaints in which they had been claimed that they had born children with autism after using them.
However, a federal judge in Manhattan decided in 2023 that some of these complaints had no scientific evidence and later ended the legal disputes in 2024. Some examinations have also not found a connection between acetaminophs and autism.
In a note on Friday, the BNP Paribas analyst Navann Ty said that the company believes that the “hurdle for the cause of the evidence [between the drug and autism] Is high, especially in view of the fact that the legal dispute, which was previously closed in favor of Kenvuen. “
– Angelica Peebles from CNBC contributed to this report.
